- Trials with a EudraCT protocol (105)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
105 result(s) found for: Visual memory.
Displaying page 1 of 6.
EudraCT Number: 2014-003117-28 | Sponsor Protocol Number: EPU-P77 | Start Date*: 2014-11-03 | ||||||||||||||||
Sponsor Name: | ||||||||||||||||||
Full Title: Can Methylphenidate (Ritalin) improve memory and attention in mild cognitive impairment? An EEG study | ||||||||||||||||||
Medical condition: memory impairment in patients with Mild Cognitive Impairment | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-024543-33 | Sponsor Protocol Number: P64 | Start Date*: 2011-04-14 |
Sponsor Name:Maastricht University | ||
Full Title: Can memantine prevent memory impairment induced by MDMA in humans | ||
Medical condition: none | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-002027-26 | Sponsor Protocol Number: 2405 | Start Date*: 2016-04-13 |
Sponsor Name:University of Bristol | ||
Full Title: TARGETING DOPAMINE TO TREAT IMPAIRED MEMORY CONSOLIDATION IN NEURODEGENERATIVE DISEASE: A DOUBLE-BLIND PLACEBO-CONTROLLED TRIAL | ||
Medical condition: Mild Cognitive Impairment Mild Alzheimer's disease | ||
Disease: | ||
Population Age: Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2007-001520-12 | Sponsor Protocol Number: D1443C00013 | Start Date*: 2008-01-11 |
Sponsor Name:Unidade de Investigação em Saúde Mental e Psiquiatria do Centro Hospitalar Conde de Ferreira | ||
Full Title: Efficacy and distinctive effects of atypical antipsychotics on cognitive symptoms in dual diagnosis – A phase IIIb, randomized, open-labelled study to evaluate the cognitive effects of quetiapine X... | ||
Medical condition: Patients with both schizophrenia and substance abuse disorder | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: PT (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2012-001599-12 | Sponsor Protocol Number: 18F-AV-45-C01 | Start Date*: 2014-03-04 |
Sponsor Name:VU University Medical Center (VUmc) | ||
Full Title: The clinical value of amyloid imaging with [18F]-AV45 in a population of memory clinic patients | ||
Medical condition: The total number of inclusion in this study is 170 subjects; 140 patients (including Alzheimer’s disease (AD) patients, patients with mild cognitive impairment (MCI), patients with subjective memor... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: NL (Prematurely Ended) | ||
Trial results: (No results available) |
EudraCT Number: 2015-005780-16 | Sponsor Protocol Number: 1042_OPBG_2016 | Start Date*: 2019-04-10 |
Sponsor Name:IRCCS Bambino Gesù Children's Hospital | ||
Full Title: A phase 2 controlled study with blinded outcome assessment on the efficacy of Bumetanide vs no drug treatment for cognitive improvement to rescue cognitive functions in children and adolescents wit... | ||
Medical condition: Down Syndrome | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: IT (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2016-004955-64 | Sponsor Protocol Number: E2090-S082-403 | Start Date*: 2017-04-21 |
Sponsor Name:Eisai Korea Inc. | ||
Full Title: A Multicenter Comparative Trial of Zonisamide and Topiramate as Monotherapy in Epilepsy Patients: Safety for cognitive function | ||
Medical condition: Epilepsy | ||
Disease: | ||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: (No results available) |
EudraCT Number: 2009-010227-62 | Sponsor Protocol Number: GE-067-005 | Start Date*: 2009-09-09 | |||||||||||
Sponsor Name:GE Healthcare Ltd and its Affiliates | |||||||||||||
Full Title: A Principal Open-label Study to Assess the Prognostic Usefulness of Flutemetamol (F18) Injection for Identifying Subjects with Amnestic Mild Cognitive Impairment who will Convert to Probable Alzhei... | |||||||||||||
Medical condition: GE-067-005 will investigate the efficacy of the Flutemetamol (18F) Injection PET tracer for predicting the conversion from amnestic Mild Cognitive Impairment to probable Alzheimer’s disease. Uptake... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-004396-23 | Sponsor Protocol Number: N01103 | Start Date*: 2015-02-27 | |||||||||||
Sponsor Name:UCB, Inc. | |||||||||||||
Full Title: A 19-week, Randomized, Double-blind, Multicenter, Placebo-controlled Safety Study to Evaluate the Cognitive and Neuropsychological Effects of Levetiracetam 20-60 mg/kg/day, Divided in Twice Daily D... | |||||||||||||
Medical condition: Epilepsy, Partial | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-003271-35 | Sponsor Protocol Number: KU-AIM-01-2018 | Start Date*: 2019-01-07 | |||||||||||
Sponsor Name:University of Copenhagen | |||||||||||||
Full Title: STUDY OF ATTENTION AND IMPULSIVITY IN HEALTHY HUMAN VOLUNTEERS | |||||||||||||
Medical condition: Attentional deficits and impulsive behaviour. These symptoms are common in attention deficit hyperactivity disorder, but also other conditions affecting the central nervous system such as Alzheimer... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2005-003410-15 | Sponsor Protocol Number: 6251 7976 | Start Date*: 2005-11-21 |
Sponsor Name:Neurology Unit | ||
Full Title: A twelve-month double-blind placebo-controlled cross-over study of the effect ofAricept treatment on cognitive dysfunction in multiple sclerosis. | ||
Medical condition: Multiple sclerosis is a devastating inflammation in the central nervous system and it can often give cognitive dysfunction, affecting memory, mental concentration. Lately it has been shown that the... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: SE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2004-005078-22 | Sponsor Protocol Number: QUETIAPINKOGNSCHIZOPHR | Start Date*: 2005-04-18 |
Sponsor Name:Medical School of Hannover | ||
Full Title: Quetiapin: Zur Sicherheit, Verträglichkeit und zum Einfluss auf kognitive Funktionen bei Patienten/innen mit einer schizophrenen Psychose Quetiapine: safety and influence on cognitive functions i... | ||
Medical condition: Patients with schizophrenia, who are not in an acute state of psychosis at enrolment (PANSS score < 80) and who do not show criteria of moderate depression, but may show depression-like symptoms co... | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2005-005307-42 | Sponsor Protocol Number: S2540345 | Start Date*: 2006-01-03 |
Sponsor Name:GlaxoSmithKline Consumer Healthcare | ||
Full Title: An evaluation of the 4 mg nicotine mint lozenge for the relief of cognitive impairment associated with nicotine withdrawal. | ||
Medical condition: Nicotine dependence. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2009-011582-88 | Sponsor Protocol Number: 41470956 | Start Date*: 2009-05-28 | |||||||||||
Sponsor Name:St James Hospital | |||||||||||||
Full Title: The differential effects of donepezil and placebo on EEG/ ERP measures and fMRI in mild cognitive impairment and elderly controls | |||||||||||||
Medical condition: Amnestic Mild cognitive Impairment (aMCI) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002326-36 | Sponsor Protocol Number: 2016-858 | Start Date*: 2016-11-09 | ||||||||||||||||
Sponsor Name:Region Hovedstadens psykiatriske hospital | ||||||||||||||||||
Full Title: Effects of erythropoietin (EPO) on cognitive side-effects of electroconvulsive therapy (ECT) (EPO-T) | ||||||||||||||||||
Medical condition: Unipolar/bipolar depression | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: DK (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2017-002204-27 | Sponsor Protocol Number: GS030_CLIN_001 | Start Date*: 2017-12-22 |
Sponsor Name:GENSIGHT-BIOLOGICS | ||
Full Title: A Phase 1/2a, Open-Label, Non-Randomized, Dose-Escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects with Retinitis Pigmentosa | ||
Medical condition: Retinitis Pigmentosa | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2007-006487-30 | Sponsor Protocol Number: 150662 | Start Date*: 2009-09-11 | |||||||||||
Sponsor Name:St. James's Hospital | |||||||||||||
Full Title: Differential Effects of donepezil and placebo in mild cognitive impairment and elderly controls. | |||||||||||||
Medical condition: Amnestic Mild Cognitive Impairment (aMCI) | |||||||||||||
|
|||||||||||||
Population Age: Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-002147-34 | Sponsor Protocol Number: AZT-001 | Start Date*: 2016-01-21 | |||||||||||
Sponsor Name:AZTherapies, Inc. | |||||||||||||
Full Title: A phase III Safety and Efficacy Study of ALZT-OP1 in Subjects with Evidence of Early Alzheimer’s Disease. | |||||||||||||
Medical condition: Early stage of Alzheimer's Disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) CZ (Completed) BG (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004388-11 | Sponsor Protocol Number: EIP-VX17-745-304 | Start Date*: 2018-10-11 | |||||||||||
Sponsor Name:EIP Pharma Inc | |||||||||||||
Full Title: A Double-Blind, Placebo-Controlled Proof-of-Concept Study of a Selective p38 MAP Kinase Alpha Inhibitor, Neflamapimod, Administered for 24 Weeks in Subjects with Mild Alzheimer’s Disease | |||||||||||||
Medical condition: Alzheimer's Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DK (Completed) NL (Completed) CZ (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-000235-28 | Sponsor Protocol Number: 190-060 | Start Date*: 2004-10-27 |
Sponsor Name:Sepracor Inc. | ||
Full Title: The effects of a single evening dose of 3mg eszopiclone on next day driving ability and psychomotor/memory function in patients with primary insomnia compared to placebo | ||
Medical condition: Insomnia | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: GB (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
